Aging and the cancer burden in Latin America and the Caribbean: Time to act

Pilleron, Sophie; Soerjomataram, Isabelle; Soto‐Pérez‐de‐Celis, Enrique; Ferlay, Jacques; Vega, Enrique; Bray, Freddie; Piñeros, Marion

doi:10.1016/j.jgo.2019.02.014

Cited by 24 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, older women who develop cervical cancer are also more likely to be diagnosed with advanced-stage disease, contributing to higher mortality rates in this age group 39 . With the expected population growth among older women in the LAC region over the next decades 40 , there is an overwhelming need for cervical cancer control programs and policies tailored to older women in LAC countries/territories. This study has reported increased incidence rates among the youngest age group (0-29 years) in some certain cancer registries in the LAC region, although incidence and mortality estimates in this group should be interpreted with caution due to the relatively small number of cases and deaths.…”

Section: Discussionmentioning

confidence: 99%

Cervical cancer burden in Latin America and the Caribbean: Where are we?

Pilleron

Cabasag

Ferlay

et al. 2020

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Novelty and ImpactWe described the cervical cancer incidence and mortality in Latin America and the Caribbean.In 2018, we estimated 56,000 and 28,000 new cervical cancer cases and deaths, respectively, with great variations between countries/territories. Despite a recent decrease in cervical cancer incidence and mortality rates, they are still high. Thus, achieving the elimination of cervical cancer in the Region still requires substantial effort, including the establishment of populationbased cancer registries.

show abstract

Section: Discussionmentioning

confidence: 99%

Cervical cancer burden in Latin America and the Caribbean: Where are we?

Pilleron

Cabasag

Ferlay

et al. 2020

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…In these previous studies more mutations were described in BRCA2 than in BRCA1 with some of them being population-specific mutations [22,44]. A plausible explanation is that the Uruguayan population is the most aged in South America [45], and BRCA2 mutations are slightly more common between older women with sporadic breast cancer [46]. Moreover, an association of common variants in genes, such as FGFR2 (rs2981582) and MAP3K1 (rs16886165), with BRCA2 mutant carriers, has been described [47], but it is not present in our study (data not shown).…”

Section: Discussionmentioning

confidence: 99%

Genomic Diversity in Sporadic Breast Cancer in a Latin American Population

Brignoni

Cappetta

Colistro

et al. 2020

Genes

View full text Add to dashboard Cite

Among Latin American women, breast cancer incidences vary across populations. Uruguay and Argentina have the highest rates in South America, which are mainly attributed to strong, genetic European contributions. Most genetic variants associated with breast cancer were described in European populations. However, the vast majority of genetic contributors to breast cancer risk remain unknown. Here, we report the results of a candidate gene association study of sporadic breast cancer in 176 cases and 183 controls in the Uruguayan population. We analyzed 141 variants from 98 loci that have been associated with overall breast cancer risk in European populations. We found weak evidence for the association of risk variants rs294174 (ESR1), rs16886165 (MAP3K1), rs2214681 (CNTNAP2), rs4237855 (VDR), rs9594579 (RANKL), rs8183919 (PTGIS), rs2981582 (FGFR2), and rs1799950 (BRCA1) with sporadic breast cancer. These results provide useful insight into the genetic susceptibility to sporadic breast cancer in the Uruguayan population and support the use of genetic risk scores for individualized screening and prevention.

show abstract

“…In Latin America, it is the most frequently diagnosed cancer in men and has an age-standardized incidence rate of 60.4 per 100,000 with a mortality rate of 14 per 100,000 [1]. The burden of disease is expected to double in this region by 2030 owing to an increase in the aged male population [2,3].…”

Section: Introductionmentioning

confidence: 99%

AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis

et al. 2020

View full text Add to dashboard Cite

Background. Prostate cancer is the most incident and one of the deadliest male cancers in Latin America. Treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) includes androgen receptor signaling inhibitors such as abiraterone and enzalutamide, for which androgen receptor splice variant 7 (AR-V7) has emerged as a biomarker for primary resistance. Our study sought to analyze the potential economic impact of the use of AR-V7 detection as a treatment indicator in patients with mCRPC in three Latin American countries. Materials and Methods. A hypothetical cost prediction model for the use of noninvasive circulating tumor cellbased AR-V7 testing as a treatment indicator for patients eligible for treatment with abiraterone/enzalutamide was conducted using available information on treatment and testing costs from Mexico, Argentina, and Colombia.

show abstract

Aging and the cancer burden in Latin America and the Caribbean: Time to act

Cited by 24 publications

References 26 publications

Cervical cancer burden in Latin America and the Caribbean: Where are we?

Cervical cancer burden in Latin America and the Caribbean: Where are we?

Genomic Diversity in Sporadic Breast Cancer in a Latin American Population

AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis

Contact Info

Product

Resources

About